Cart
sales@molnova.com
Zongertinib
CAS No. 2728667-27-2
Zongertinib( —— )
Catalog No. M36284 CAS No. 2728667-27-2
Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (TKD).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 225 | Get Quote |
|
| 5MG | 353 | Get Quote |
|
| 10MG | 471 | Get Quote |
|
| 25MG | 685 | Get Quote |
|
| 50MG | 891 | Get Quote |
|
| 100MG | 1107 | Get Quote |
|
| 200MG | 1503 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameZongertinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionZongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (TKD).
-
DescriptionZongertinib (BI 1810631) is a potent and selective HER2 and EGFR tyrosine kinase inhibitor with IC50 values of 13 nM and 579 nM, respectively. Zongertinib has antitumor activity and can be used in the study of multiple solid tumors.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetHER/HSP
-
RecptorHER | Tyrosine Kinases
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2728667-27-2
-
Formula Weight535.6
-
Molecular FormulaC29H29N9O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 31.25 mg/mL (58.35 mM; Ultrasonic (<60°C)
-
SMILESN(C=1C2=C(C=NC(=N2)N3CCC(NC(C=C)=O)CC3)N=CN1)C4=CC(C)=C(OC=5C=C6C(=CC5)N(C)C=N6)C=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. WHO Drug Informat ion - World Health Organization (WHO).
molnova catalog
related products
-
PF-04929113
PF-04929113 (SNX-5422) is a potent and selective HSP90 inhibitor with Kd of 41 nM and induces Her-2 degradation with IC50 of 37 nM. Phase 1/2.
-
BMS 599626 2HCl
BMS-599626 (AC480) is a selective inhibitor of HER1 and HER2 (IC50s: 20 nM and 30 nM) ~8-fold less potent to HER4 >100-fold to Lck VEGFR2 c-Kit MET etc.
-
Trastuzumab
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.
